{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:38:24Z","timestamp":1774384704555,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovation Group Project of Shanghai Municipal Health Commission","award":["2019CXJQ03"],"award-info":[{"award-number":["2019CXJQ03"]}]},{"DOI":"10.13039\/100012543","name":"Shanghai Science and technology development fund","doi-asserted-by":"crossref","award":["19MC1911000"],"award-info":[{"award-number":["19MC1911000"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Key Clinical Specialty","award":["shslczdzk01301"],"award-info":[{"award-number":["shslczdzk01301"]}]},{"name":"Innovation Program of Shanghai Science and Technology Committee","award":["20Z11900300"],"award-info":[{"award-number":["20Z11900300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02086-7","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:49:20Z","timestamp":1771836560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of cancer stem cell mechanism and immune profiling in breast cancer of unknown primary"],"prefix":"10.1007","volume":"26","author":[{"given":"Min","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2086_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41571-020-0359-1","volume":"17","author":"E Rassy","year":"2020","unstructured":"Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Reviews Clin Oncol. 2020;17:541\u201354.","journal-title":"Nat Reviews Clin Oncol"},{"key":"2086_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMra1303917","volume":"371","author":"GR Varadhachary","year":"2014","unstructured":"Varadhachary GR, Raber MN. Cancer of unknown primary site. New Engl J Med. 2014;371:757\u201365.","journal-title":"New Engl J Med"},{"key":"2086_CR3","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379:1428\u201335.","journal-title":"Lancet"},{"key":"2086_CR4","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","volume":"158","author":"KA Hoadley","year":"2014","unstructured":"Hoadley KA, Yau C. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158:929\u201344.","journal-title":"Cell"},{"key":"2086_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10585-021-10073-3","volume":"38","author":"L Meijer","year":"2021","unstructured":"Meijer L, Verhoeven RHA, de Hingh IHJT, et al. Extensive diagnostic work-up for patients with carcinoma of unknown primary. Clin Exp Metastas. 2021;38:231\u20138.","journal-title":"Clin Exp Metastas"},{"key":"2086_CR6","doi-asserted-by":"publisher","first-page":"102204","DOI":"10.1016\/j.ctrv.2021.102204","volume":"97","author":"T Olivier","year":"2021","unstructured":"Olivier T, Fernandez E, Labidi-Galy I, et al. Redefining cancer of unknown primary: is precision medicine really shifting the paradigm? Cancer. Treat Rev. 2021;97:102204.","journal-title":"Treat Rev"},{"key":"2086_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrclinonc.2017.97","volume":"14","author":"S Moran","year":"2017","unstructured":"Moran S, Martinez-Card\u00fas A, Boussios S, Esteller M. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol. 2017;14:682\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"2086_CR8","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","volume":"25","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang X, Jiang S, et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. Lancet Oncol. 2024;25:1092\u2013102.","journal-title":"Lancet Oncol"},{"key":"2086_CR9","doi-asserted-by":"crossref","unstructured":"Bochtler T, Kr\u00e4mer A. Does cancer of unknown primary (CUP) truly exist as a distinct cancer entity? Front. Oncol. 2019;17:402.","DOI":"10.3389\/fonc.2019.00402"},{"key":"2086_CR10","doi-asserted-by":"crossref","unstructured":"Vikes\u00e5 J, M\u00f8ller AKH, Kaczkowski B et al. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin. BMC Cancer 2015;15:151.","DOI":"10.1186\/s12885-015-1128-x"},{"key":"2086_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/eci.12062","volume":"43","author":"K Kamposioras","year":"2013","unstructured":"Kamposioras K, Pentheroudakis G, Pavlidis N. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. Eur J Clin Invest. 2013;43:491\u2013500.","journal-title":"Eur J Clin Invest"},{"key":"2086_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ccr.2013.09.007","volume":"24","author":"S Vanharanta","year":"2013","unstructured":"Vanharanta S, Massagu\u00e9 J. Origins of metastatic traits. Cancer Cell. 2013;24:410\u201321.","journal-title":"Cancer Cell"},{"key":"2086_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11523-017-0508-3","volume":"12","author":"JD Lathia","year":"2017","unstructured":"Lathia JD, Liu H. Overview of cancer stem cells and stemness for community oncologists. Target Oncol. 2017;12:387\u201399.","journal-title":"Target Oncol"},{"key":"2086_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-023-01748-4","volume":"22","author":"B Wu","year":"2023","unstructured":"Wu B, Shi X, Jiang M, Liu H. Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Mol Cancer. 2023;22:38\u201338.","journal-title":"Mol Cancer"},{"key":"2086_CR15","doi-asserted-by":"crossref","unstructured":"Haratani K, Hayashi H, Takahama T et al. Clinical and immune profiling for cancer of unknown primary site. J Immunother Cancer 2019;7:251.","DOI":"10.1186\/s40425-019-0720-z"},{"key":"2086_CR16","doi-asserted-by":"publisher","first-page":"e005809","DOI":"10.1136\/jitc-2022-005809","volume":"11","author":"T A.Posner","year":"2023","unstructured":"A.Posner T, Sivakumaran A, Pattison, et al. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. J Immunother Cancer. 2023;11:e005809.","journal-title":"J Immunother Cancer"},{"key":"2086_CR17","doi-asserted-by":"crossref","unstructured":"Andersen L, Christensen DS, Kjaer A et al. Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers. Mol Oncol 2024;18:2393-406.","DOI":"10.1002\/1878-0261.13664"},{"key":"2086_CR18","doi-asserted-by":"crossref","unstructured":"Qi P, Sun Y, Liu X et al. Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in china: an analysis of 1420 cases. Cancer Medi 2023;12:1177-88.","DOI":"10.1002\/cam4.4973"},{"key":"2086_CR19","doi-asserted-by":"crossref","unstructured":"Ren M, Cai X, Jia L et al. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China. BMC Cancer 2023;23:1175.","DOI":"10.1186\/s12885-023-11563-1"},{"key":"2086_CR20","doi-asserted-by":"publisher","first-page":"vi64","DOI":"10.1093\/annonc\/mdr389","volume":"22","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals Oncol. 2011;22:vi64\u201368.","journal-title":"Annals Oncol"},{"key":"2086_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Annals Oncol. 2015;26:259\u201371.","journal-title":"Annals Oncol"},{"key":"2086_CR22","doi-asserted-by":"crossref","unstructured":"Tang L, Zhu Y, Du Y et al. Clinicopathologic features and genomic profiling of female axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary. J Cancer Res Clin Oncol 2024;150:256.","DOI":"10.1007\/s00432-024-05783-6"},{"key":"2086_CR23","doi-asserted-by":"crossref","unstructured":"Cristescu R, Mogg R, Ayers M et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science 2018;362:eaar3593.","DOI":"10.1126\/science.aar3593"},{"key":"2086_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41586-023-05806-1","volume":"616","author":"JS Weinstock","year":"2023","unstructured":"Weinstock JS, Gopakumar J, Burugula BB, et al. Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature. 2023;616:755\u201363.","journal-title":"Nature"},{"key":"2086_CR25","doi-asserted-by":"crossref","unstructured":"Paduano F, Gaudio E, Mensah AA, Pinton S, Bertoni F. F. Trapasso. T-Cell Leukemia\/Lymphoma 1 (TCL1): an oncogene regulating multiple signaling pathways. Front Oncol 2018;8:317.","DOI":"10.3389\/fonc.2018.00317"},{"key":"2086_CR26","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.3390\/cancers13215455","volume":"13","author":"J Stachelscheid","year":"2021","unstructured":"Stachelscheid J, Jiang Q, Herling M. The modes of dysregulation of the Proto-Oncogene T-Cell Leukemia\/Lymphoma 1A. Cancers. 2021;13:5455.","journal-title":"Cancers"},{"key":"2086_CR27","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1136\/gutjnl-2013-305302","volume":"63","author":"X Hong","year":"2014","unstructured":"Hong X, Song R, Song H, et al. PTEN antagonises Tcl1\/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut. 2014;63:1635\u201347.","journal-title":"Gut"},{"key":"2086_CR28","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1172\/JCI64057","volume":"122","author":"KH Noh","year":"2012","unstructured":"Noh KH, Kim BW, Song K, et al. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest. 2012;122:4077\u201393.","journal-title":"J Clin Invest"},{"key":"2086_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41420-023-01759-6","volume":"9","author":"VR Silva","year":"2023","unstructured":"Silva VR, Santos LDS, de Castro MVL, et al. A novel ruthenium complex with 5-fluorouracil suppresses colorectal cancer stem cells by inhibiting Akt\/mTOR signaling. Cell Death Discov. 2023;9:460\u2013413.","journal-title":"Cell Death Discov"},{"key":"2086_CR30","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ijc.30834","volume":"141","author":"S Almozyan","year":"2017","unstructured":"Almozyan S, Colak D, Mansour F, et al. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K\/AKT pathway activation. Int J Cancer. 2017;141:1402\u201312.","journal-title":"Int J Cancer"},{"key":"2086_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10585-012-9548-3","volume":"30","author":"G Pentheroudakis","year":"2013","unstructured":"Pentheroudakis G, Spector Y, Krikelis D, et al. Global MicroRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. Clin Exp Metastas. 2013;30:431\u20139.","journal-title":"Clin Exp Metastas"},{"key":"2086_CR32","doi-asserted-by":"crossref","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 2018;11:39.","DOI":"10.1186\/s13045-018-0582-8"},{"key":"2086_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","volume":"33","author":"J Tanizaki","year":"2022","unstructured":"Tanizaki J, Yonemori K, Akiyoshi K, et al. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Annals Oncol. 2022;33:216\u201326.","journal-title":"Annals Oncol"},{"key":"2086_CR34","doi-asserted-by":"crossref","unstructured":"Pouyiourou M, Kraft BN, Wohlfromm T et al. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat Commun 2023;14:6761.","DOI":"10.1038\/s41467-023-42400-5"},{"key":"2086_CR35","doi-asserted-by":"crossref","unstructured":"Clynick B, Dessauvagie B, Sterrett G et al. Genetic characterisation of molecular targets in carcinoma of unknown primary. J Trans Medi 2018;16:185.","DOI":"10.1186\/s12967-018-1564-x"},{"key":"2086_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","volume":"1","author":"JS Ross","year":"2015","unstructured":"Ross JS, Wang K, Gay L, et al. Comprehensive genomic profiling of carcinoma of unknown primary site. JAMA Oncol. 2015;1:40.","journal-title":"JAMA Oncol"},{"key":"2086_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrclinonc.2017.198","volume":"15","author":"L Sansregret","year":"2018","unstructured":"Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018;15:139\u201350.","journal-title":"Nat Rev Clin Oncol"},{"key":"2086_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ejca.2022.06.017","volume":"172","author":"A Chebly","year":"2022","unstructured":"Chebly A, Yammine T, Boussios S, Pavlidis N. Rassy. Chromosomal instability in cancers of unknown primary. Eur J Cancer. 2022;172:323\u20135.","journal-title":"Eur J Cancer"},{"key":"2086_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.18632\/oncoscience.159","volume":"2","author":"M L\u00f3pez-L\u00e1zaro","year":"2015","unstructured":"L\u00f3pez-L\u00e1zaro M. The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking Metastasis Oncoscience. 2015;2:467\u201375.","journal-title":"Rethinking Metastasis Oncoscience"},{"key":"2086_CR40","doi-asserted-by":"crossref","unstructured":"Bruttel VS, Wischhusen JR. Cancer stem cell immunology: key to Understanding tumorigenesis and tumor immune escape? Front Immunol 2014;5:360.","DOI":"10.3389\/fimmu.2014.00360"},{"key":"2086_CR41","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12094-013-1139-5","volume":"16","author":"A Stoyianni","year":"2014","unstructured":"Stoyianni A, Pentheroudakis G, Benjamin H, et al. Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global MicroRNA profiling study. Clin Trans Oncol. 2014;16:725\u201331.","journal-title":"Clin Trans Oncol"},{"key":"2086_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5115\/acb.2014.47.1.1","volume":"47","author":"S Amini","year":"2014","unstructured":"Amini S, Fathi F, Mobalegi J, Sofimajidpour H. Ghadimi. The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines. Anat Cell Biol. 2014;47:1.","journal-title":"Anat Cell Biol"},{"key":"2086_CR43","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/PAS.0b013e3181db84aa","volume":"34","author":"A Liu","year":"2010","unstructured":"Liu A, Cheng L, Du J, et al. Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol. 2010;34:697\u2013706.","journal-title":"Am J Surg Pathol"},{"key":"2086_CR44","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood.2022018435","volume":"141","author":"AA Sahasrabuddhe","year":"2023","unstructured":"Sahasrabuddhe AA, Elenitoba-Johnson K. TCL1A expression promotes aggressive biology in CLL. Blood. 2023;141:1371\u20133.","journal-title":"Blood"},{"key":"2086_CR45","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.biopha.2017.01.128","volume":"88","author":"H Li","year":"2017","unstructured":"Li H, Yan X, Liu L, et al. T-cell leukemia\/lymphoma-1A predicts the clinical outcome for patients with stage II\/III colorectal cancer. Biomed Pharmacother. 2017;88:924\u201330.","journal-title":"Biomed Pharmacother"},{"key":"2086_CR46","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/tbj.13684","volume":"26","author":"MK Srour","year":"2020","unstructured":"Srour MK, Gao B, Dadmanesh BF, et al. Gene expression comparison between primary triple-negative breast cancer and paired axillary and Sentinel lymph node metastasis. Breast J. 2020;26:904\u201310.","journal-title":"Breast J"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02086-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02086-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02086-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:07:51Z","timestamp":1774372071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02086-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02086-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations, and all experimental protocols were approved by the Institutional Ethics Committee of Fudan University Shanghai Cancer Center. The study was reported in accordance with ARRIVE guidelines","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication has been obtained from the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"192"}}